ABBV-101 is positioned as a novel therapeutic option for patients with relapsed or refractory B-cell malignancies, particularly non-Hodgkin's lymphoma (NHL). The study's design includes a dose escalation phase followed by dose expansion, which may provide valuable data on safety and efficacy. The market for NHL therapies is competitive, with existing treatments including BTK inhibitors and BCL-2 inhibitors like venetoclax. ABBV-101's unique mechanism as a BTK degrader could differentiate it from current therapies, potentially capturing market share in a growing segment. Given the high unmet need in R/R NHL, successful outcomes could lead to significant commercial opportunities. However, the treatment burden may impact patient recruitment and retention, necessitating careful management of participant expectations and experiences.